APRELIEVA 125MG
Aprepitant Capsules IP 125mg
APRELIEVA 125 MG (Aprepitant Capsules IP 125 mg) is an antiemetic medicine used to help prevent nausea and vomiting caused by chemotherapy treatment and certain medical procedures. It contains Aprepitant, a neurokinin-1 (NK1) receptor antagonist that works by blocking specific signals in the brain responsible for triggering nausea and vomiting. Cancer patients undergoing chemotherapy often experience severe nausea and vomiting as side effects of anticancer treatment. These symptoms can affect overall health, appetite, energy levels, and quality of life. APRELIEVA 125 MG is specially formulated to help reduce chemotherapy-induced nausea and vomiting (CINV), making cancer treatment more manageable and comfortable for patients. Aprepitant works differently from traditional anti-nausea medicines. It targets substance P, a natural chemical in the brain associated with the vomiting reflex. By blocking NK1 receptors, APRELIEVA helps prevent both acute and delayed nausea and vomiting that may occur during or after chemotherapy sessions. This medicine is commonly prescribed along with other antiemetic medicines such as: • Ondansetron • Dexamethasone • Other supportive cancer care medicines APRELIEVA 125 MG is widely used in: • Chemotherapy-induced nausea prevention • Delayed vomiting prevention after chemotherapy • Supportive oncology care • Cancer treatment management programs • Certain surgery-related nausea prevention protocols under medical supervision The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. APRELIEVA should only be used under the guidance of qualified healthcare professionals. Doctors may prescribe this medicine before chemotherapy sessions to help improve patient comfort and treatment tolerance. Effective nausea management is important because uncontrolled vomiting may lead to dehydration, weakness, nutritional problems, and difficulty continuing cancer treatment. Patients using APRELIEVA 125 MG may require individualized dosing schedules depending on the type of chemotherapy, severity of symptoms, and overall treatment plan. Proper medical supervision helps improve treatment effectiveness and reduce complications. Due to its effectiveness in supportive oncology care and chemotherapy-related symptom management, APRELIEVA 125 MG has become an important medicine in modern cancer care protocols.
View Details
